Pakṣāghāta, described in Āyurveda as a severe neurological disorder caused primarily by Vāta Prakopa, closely resembles cerebrovascular accidents (CVA) in modern medicine, including both ischemic and haemorrhagic strokes. Vāta vitiation may occur due to Āghāta (trauma), faulty Āhāra-Vihāra (diet and lifestyle), and Rakta-Duṣṭi (vitiation of blood). Further study is required to figure out how Rakta Duṣṭi contributes to the etiopathogenesis of Pakṣāghāta. To evaluate the contribution of Rakta Duṣṭi in Pakṣāghāta by assessing its association with haematological parameters, specifically red blood cell (RBC) indices and platelet indices. A comprehensive literature review was conducted using references from the Bṛhattrayī and their classical commentaries, along with modern medical literature on cerebrovascular pathology. The study examined the conceptual correlation between Pakṣāghāta and Rakta Duṣṭi, and analysed the relevance of red cell and platelet indices in understanding the pathogenesis. The review indicates that alterations in RBC and platelet indices reflect underlying Rakta Duṣṭi, which may contribute role in the Samprāpti (pathogenesis) of Pakṣāghāta. Such findings highlight the interplay between Vāta vitiation and Rakta abnormalities, bridging Āyurvedic concepts with modern haematological evidence. Exploring Rakta Duṣṭi through RBC and platelet indices provides deeper insights into the etiopathogenesis of Pakṣāghāta. Understanding Samprāpti Vighaṭana from both Āyurvedic and modern perspectives can aid in preventive strategies, early diagnosis, and integrative management of cerebrovascular accidents.
Cervical spondylotic radiculopathy (CSR) is a clinical condition resulting from the compression of cervical nerve roots. While modern medicine offers various conservative and surgical interventions, these options may present limitations or potential complications for some patients. A 45-year-old female presented with a 7-year history of neck pain (Visual Analog Scale [VAS] 6), stiffness, and grade 4/5 muscle power in the right upper limb. The patient was managed with four sittings of Agnikarma and three sittings of Sirāvedha. Adjuvant oral medications included Rāsnā Saptak Kwātha and Eraṇḍamūla Kwātha for 3.5 months, Ashwagandhāriṣṭa and Navajīvana Rasa for 3 weeks, and Kārpasasthyādi Taila orally for 10 months. After a total treatment timeline of 10 months, pain resolved completely (VAS 0) and muscle power improved to grade 5/5. Follow-ups at 6 and 12 months, based on telephonic self-reported history, confirmed no recurrence of symptoms. This case demonstrates that a multimodal Ayurveda approach can effectively manage CSR.
Background: In India, the incidence of fistula-in-ano was found to be approximately 8.6 per 1 lakh population and male-to-female ratio was 11.8:1. It is considered among Ashtamahagada by Acharya Suśrut, which bespeaks the gravity of this disease with treatment by different means. Materials and Methods: One hundred and six patients of Bhagandaraḥ (fistula in ano) were selected and randomly allocated into two groups using the computerized randomization table. In Group A (n = 53), patients were treated by fistulotomy with Kṣāra application, whereas in Group B (n = 53), patients were treated with Kṣārasutra (KS) application. In both groups, adjuvant treatment such as hot sitz bath was advised with 5 L of Panchavalkala Kwatha twice a day. Mātrābasti (60 mL) of Jatyadi Taila was given, once a day after sitz bath in the morning. Varuna Śigru Guggulu Vati 1 g thrice a day was given with lukewarm water after meals till complete cure. In Group A, dressing was done with Kṣāra Plota (gauze dipped in Kṣāra jala) till the postoperative wound had slough, followed by dressing with gauze socked in normal saline. In Group B, the tract was flushed with Kṣāra jala every day and KS was changed by rail road method every week till the cut through of fistulous tract. Results: The comparison of mean change in pain score from before to after treatment periods showed that there was significant (P = 0.0001) mean change in pain score in both the groups. At the end of treatment showed that pain was improved in 96.1% patients of Group A and 96% patients of Group B. Discharge was improved in 100% patients of Group A and 96% patients of Group B. Itching was improved in 98.1% patient of Group A and 94% patient of Group B. Conclusion: Fistulotomy and Kṣāra karma was better as compared to KS application in the management of Bhagandaraḥ.
Introduction: This study is a clinical trial to evaluate the effect of the drug Bhallātakādi Taila on Dadru Kuṣṭa. As there is a quote from Caraka Saṃhita “Yogādapi Viṣam Tīkṣṇam Uttamam Bheṣajam Bhavet, Bheṣajam Cāpi Duryuktam Tīkṣṇam Sampadyate Viṣam” which says when a poison is used in a proper dose acts as nectar and medicine is used in an improper dose acts as poison. Present clinical evidence is an example how the poisonous drugs when properly processed and purified have shown the efficacious results. Clinically, we can consider Dadru Kuṣṭa similar to that of dermatophytosis as the manifestations converge. Hence, this clinical study has shown the efficacy of Bhallātakādi Taila in Dadru Kuṣṭa. Objectives: (1) To study the clinical effect of Bhallātakādi Taila in the management of Dadru Kuṣṭa w.s.r. dermatophytosis. (2) To conduct the Pharmaceutico-analytical study of Bhallātakādi Taila. Methods: The study was selected after the approval of institutional ethical committee. This is a single-group clinical trial of 30 subjects conducted in Shri Dharmasthala Manjunatheshwara Āyurveda College and Hospital, Kuthpady, Udupi, Karnataka. Thirty (n = 30) patients of either sex diagnosed as Dadru Kuṣṭa were selected for study from outpatient department and the inpatient department. All the patients fitting the inclusion criteria and who can give consent were given Bhallātakādi Taila for external application twice a day for 28 days after the patch test. Results were analyzed before treatment, 7th, 14th, 21st, 28th, and 35th day of the course of treatment. Statistical Analysis Used: All data were tabulated, and statistical analysis was done. BT and AT results were analyzed within the group. The data obtained were statistically analyzed by Paired “t”- test and Wilcoxon signed rank test. Results: The intervention showed highly significant and statistically significant results with “P” <<0.0011. Overall assessment showed complete relief in seven patients and marked relief in 23 patients. Conclusions: Bhallātakādi Taila has shown statistically significant results, in reduction of clinical features of Dadru Kuṣṭa.
Background: Cardiovascular diseases (CVDs) remain a global health concern, with P-selectin emerging as a crucial player in their intricate pathophysiology. Using a comprehensive ELISA methodology, this study investigates P-selectin levels in 28 coronary artery disease (CAD) patients at different treatment stages. P-selectin, expressed on endothelial cells and activated platelets, plays a pivotal role in thrombotic and inflammatory processes, contributing to atherosclerotic lesions and CAD progression. Materials and Methods: Blood samples were collected after each therapeutic procedure viz. before ṣnehapana, after ṣnehapana, after Virechana therapy, and after Rasayana therapy. The Human P-Selectin ELISA kit was utilized for quantification. Statistical analyses included paired t-tests, Dunn’s Multiple Comparison Test, and Bonferroni’s Multiple Comparison Test. Results: Significant reduction in P-selectin levels were observed after Virechana (P = 0.0019) and Rasayana therapy. Dunns multiple comparison tests revealed highly significant results (P < 0.001) after Rasayana therapy, emphasizing its substantial impact. Bonferroni, a multiple comparison test, demonstrated significance (P < 0.05) after Virechana and overall treatment, highlighting the dynamic responsiveness of P-selectin to interventions. Conclusion: The findings provide valuable insights into the efficacy of each intervention in modulating P-selectin levels associated with CAD pathology. Rasayana therapy demonstrated a significant decrease in P-selectin levels, suggesting its potential therapeutic benefit. These results contribute to understanding P-selectin-mediated pathways.
